Get the Stockscreener App
32.20
0.44%
0.14
After Hours:
32.22
0.02
+0.06%
Moderna Inc stock is traded at $32.20, with a volume of 6.01M.
It is up +0.44% in the last 24 hours and up +26.03% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$32.06
Open:
$32.19
24h Volume:
6.01M
Relative Volume:
0.57
Market Cap:
$12.45B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.6884
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-6.07%
1M Performance:
+26.03%
6M Performance:
-5.46%
1Y Performance:
-74.04%
1-Day Range:
$31.97
$32.72
1-Week Range:
$31.42
$34.07
52-Week Range:
$23.15
$126.42
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
32.20 | 12.68B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Amarillo Globe-News
IBM-Moderna Showcase Quantum-Enhanced Drug Discovery - HPCwire
Nisa Investment Advisors LLC Purchases 21,330 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. - Barron's
Director, Strategic Forecasting, Oncology job with Moderna, Inc. | 1402245670 - New Scientist
Moderna’s latest approval again reveals FDA rift over COVID vaccines - BioPharma Dive
OVERSEA CHINESE BANKING Corp Ltd Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
William Blair Issues Negative Outlook for Moderna Earnings - MarketBeat
Cwm LLC Acquires 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Fully Approves Moderna’s COVID-19 Vaccine for Some Young Children - Vaccine Advisor
Lobbying Update: $100,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna gets full FDA approval for kids COVID-19 vaccine - MSN
Moderna patent for mRNA vaccine knocked back, for now - Lawyerly
Moderna: Ready For The Redemption Arc (NASDAQ:MRNA) - Seeking Alpha
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA) - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - The Motley Fool
Bank of New York Mellon Corp Has $54.38 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Why Moderna (MRNA) Stock Is Falling Today - Yahoo Finance
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults - The Globe and Mail
Class Action Filed Against Moderna, Inc. (MRNA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
What to Expect From Moderna's Next Quarterly Earnings Report - MSN
What To Expect From Moderna's Next Quarterly Earnings Report - Barchart.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Teacher Retirement System of Texas - MarketBeat
Financial Gravity Asset Management Inc. Invests $1.28 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lobbying Update: $20,000 of MODERNA INC. lobbying was just disclosed - Nasdaq
Trend Tracker for (MRNA) - news.stocktradersdaily.com
Top Large Cap Stock Gainers Last WeekModerna (NASDAQ:MRNA), Coinbase Global (NASDAQ:COIN), Delta Air Lines (NYSE:DAL) - Benzinga
Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Raised by Moloney Securities Asset Management LLC - MarketBeat
Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
FDA approves Moderna COVID-19 vaccine for high-risk children - TechTarget
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent
FDA approves Moderna's COVID vaccine for children as young as 6 months old - Scripps News
Moderna COVID shot gets FDA approval for kids 6 months to 11 years - USA Today
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients - Yahoo Finance
Moderna Wins Full Approval for COVID-19 Shot for Higher-Risk Kids - BioSpace
Moderna (NASDAQ:MRNA) Shares Up 8.4%Here's What Happened - MarketBeat
Moderna’s COVID vaccine gets full US approval for at-risk children aged 6 months and older - MSN
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease - Great Falls Tribune
FDA gives full approval to Moderna COVID shot for at-risk kids - The Hill
Moderna stock rises after FDA approves COVID-19 vaccine for at-risk children - Investing.com Nigeria
Pfizer Takes Aim At Moderna's Leftover MRNA Protections - Law360
Moderna COVID shot for kids cleared in face of RFK Jr. criticism - The Boston Globe
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Benzinga
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility - STAT
Moderna gets full US approval for COVID shot in at-risk children 6 months and older - Reuters
Moderna COVID vaccine gets full approval for children - BioPharma Dive
Why Moderna (MRNA) Stock Is Up Today - Yahoo Finance
Moderna Stock Has Risen 19% This Month. Is It Now A Buy? - Investor's Business Daily
Moderna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And Older - Stocktwits
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):